Updated:
Haisco Pharmaceutical
Founded in 2000 by Wang Junmin, Fan Xiulian, and Zheng Wei, Haisco Pharmaceutical Group is a China-based corporate investor and drug developer headquartered in...
Haisco Pharmaceutical
Founded in 2000 by Wang Junmin, Fan Xiulian, and Zheng Wei, Haisco Pharmaceutical Group is a China-based corporate investor and drug developer headquartered in Shannan, Tibet. The company went public on the Shenzhen Stock Exchange and generates its capital base from the development, production, and sale of branded generic and specialty pharmaceuticals, with a focus on anesthesia, hepatology, and oncology therapeutic areas. Haisco deploys capital primarily through direct corporate investments and strategic R&D partnerships across the biotech and pharmaceutical value chain. Its portfolio includes Chengdu Kangxin Pharmaceutical Development, Chengdu Haisco Biotechnology, and Sichuan Haisco Pharmaceutical, reflecting a vertical integration strategy that spans early-stage R&D through commercial manufacturing. The firm operates four major industrial production bases — in Liaoning, Sichuan, Shenyang, and Meishan — and maintains a US presence through a La Jolla, California office, which supports its R&D and business development activities. In 2023, Fullgoal Fund Management participated as an institutional investor in a funding round, marking an external validation of the company's corporate venture posture. Led by Chairman Wang Junmin and CEO Fan Xiulian, the company has grown a multi-site manufacturing and R&D infrastructure supported by its corporate balance sheet. The firm is an active member of PhIRDA (China Pharmaceutical Innovation and Research Development Association), connecting it to policy research and domestic innovation networks. Its subsidiary structure spans clinical development, API manufacturing, and finished-dose production, allowing it to incubate assets internally and partner selectively with external innovation in Greater China. May 2023: Fullgoal Fund Management completed an institutional investment in Haisco, as noted in corporate filings. The firm differs from a standard pharma company by maintaining a dedicated arm through Haisco-USA for in-licensing and early-stage scouting, operating a hybrid model that blends internal generic-driven cash flows with targeted external equity investments in novel therapeutic platforms.
General information
Firm type
Corporate Investor
Year founded
2000
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shannan
Corporate office
Number 17, Sanxiang Avenue, Zedang Town, Shannan, Tibet 856000, China
Additional offices
Chengdu, China · Shenyang, China · La Jolla, CA, USA
Principals
Wang Junmin
Chairman
Fan Xiulian
CEO, Vice Chairperson
Zheng Wei
Co-founder, former Director
Sector focus
Frequently asked questions
Who runs investment decisions at Haisco Pharmaceutical?
Investment and strategic decisions at Haisco are led by Chairman Wang Junmin and CEO Fan Xiulian, who co-founded the company in 2000. The corporate venture and business development functions operating out of the La Jolla, California office report into the senior leadership team in Shannan. Wang Junmin maintains oversight of the strategic investment direction, including the incubation of entities like Chengdu Haisco Biotechnology.
How does Haisco source deal flow?
Haisco sources deals through its US business development office in La Jolla, California, industry networks tied to its PhIRDA membership, and direct scouting of Chinese biotech platforms. The company targets assets that complement its internal pipeline in anesthesia, hepatology, and oncology. Its vertical integration across API manufacturing and R&D gives it direct visibility into upstream platform technologies.
Is Haisco structured solely as a pharmaceutical manufacturer, or does it function as a corporate investor?
Haisco operates a dual structure: it generates revenue from the development, production, and sale of branded generics and specialty drugs, while also making direct equity investments in biotech subsidiaries and strategic partners. Holdings such as Chengdu Kangxin Pharmaceutical Development position it as an active corporate investor, deploying balance-sheet capital to capture innovation and secure pipeline assets.
What is Haisco's geographic footprint?
Haisco's corporate headquarters is in Shannan, Tibet, with R&D and manufacturing operations distributed across four production bases in Liaoning, Sichuan, Shenyang, and Meishan. The company maintains a US business development presence through its La Jolla, California office, which supports in-licensing and partnership activities for the North American market.
Which therapeutic areas does Haisco prioritize?
Haisco concentrates on anesthesia, hepatology, and oncology as its core therapeutic areas, developing both branded generics and specialty pharmaceuticals. Its subsidiary strategy, including investments through Chengdu Haisco Biotechnology, extends this focus into earlier-stage R&D and novel drug candidates. The company avoids commoditized generics, maintaining a posture that favors higher-margin specialty products.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: